Detalhe da pesquisa
1.
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 401(10389): 1655-1668, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068504
2.
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective.
Gastric Cancer
; 27(3): 439-450, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38489111
3.
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial.
Gastric Cancer
; 27(1): 110-117, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37889360
4.
Clinical outcomes of Epstein-Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy.
Gastric Cancer
; 27(1): 146-154, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38006567
5.
Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer.
Gastric Cancer
; 2024 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555561
6.
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
Gastric Cancer
; 27(3): 558-570, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308771
7.
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Gastric Cancer
; 27(2): 375-386, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38281295
8.
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.
Br J Cancer
; 129(2): 275-282, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37179439
9.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814222
10.
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.
Gastric Cancer
; 26(4): 604-613, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36884149
11.
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.
Gastric Cancer
; 26(1): 123-131, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066725
12.
Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach.
Gastric Cancer
; 26(5): 775-787, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37351703
13.
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Oncology (Williston Park)
; 37(4): 176-183, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37104758
14.
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Future Oncol
; 19(38): 2505-2516, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37671641
15.
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Lancet Oncol
; 23(11): 1430-1440, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36244398
16.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 23(2): 234-247, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030335
17.
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Lancet Oncol
; 23(12): 1558-1570, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400106
18.
Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
Int J Cancer
; 151(10): 1770-1777, 2022 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678337
19.
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
Cancer
; 128(5): 995-1003, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34878659
20.
Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab.
Cancer Immunol Immunother
; 71(4): 829-838, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34420059